by barry101 | Feb 8, 2021 | Press Releases
HOUSTON, Feb. 8, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja...
by barry101 | Feb 3, 2021 | Press Releases
HOUSTON, Feb. 3, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Feb 2, 2021 | Press Releases
HOUSTON, Feb. 2, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Feb 2, 2021 | Press Releases
Annamycin shown to reach “sanctuary sites” of cancerHOUSTON, Feb. 2, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
by barry101 | Feb 1, 2021 | Press Releases
Annamycin being used to target soft tissue sarcoma lung metastasesHOUSTON, Feb. 1, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
by barry101 | Jan 29, 2021 | Press Releases
HOUSTON, Jan. 29, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it filed a...
